Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xenetic Biosciences (XBIO) Return on Capital Employed (2023 - 2025)

Xenetic Biosciences' Return on Capital Employed history spans 6 years, with the latest figure at 0.49% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 15.0% year-over-year to 0.49%; the TTM value through Dec 2025 reached 0.49%, up 15.0%, while the annual FY2025 figure was 0.43%, 11.0% up from the prior year.
  • Return on Capital Employed reached 0.49% in Q4 2025 per XBIO's latest filing, up from 0.81% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.43% in Q4 2023 to a low of 0.81% in Q3 2025.
  • Average Return on Capital Employed over 3 years is 0.61%, with a median of 0.63% recorded in 2023.
  • The largest YoY upside for Return on Capital Employed was 15bps in 2025 against a maximum downside of -23bps in 2025.
  • A 3-year view of Return on Capital Employed shows it stood at 0.43% in 2023, then plummeted by -48bps to 0.64% in 2024, then rose by 23bps to 0.49% in 2025.
  • Per Business Quant, the three most recent readings for XBIO's Return on Capital Employed are 0.49% (Q4 2025), 0.81% (Q3 2025), and 0.7% (Q2 2025).